TEVA
Teva Pharmaceutical Industries Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth -14.3% ·
share flow -5.8% ·
net new positions -16.7%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 151 | +7 | 369.28M | $12.48B | +9 | −1 |
| Q1 2026 | 146 | +3 | 327.68M | $9.78B | +10 | −8 |
| Q4 2025 | 144 | -1 | 326.44M | $10.18B | +3 | −3 |
| Q3 2025 | 23 | 0 | 176.53M | $3.56B | +1 | −2 |
| Q2 2025 | 21 | 0 | 197.53M | $3.31B | n/a | n/a |
| Q1 2025 | 18 | -3 | 84.56M | $1.30B | n/a | −3 |
| Q4 2024 | 21 | -1 | 89.79M | $1.98B | n/a | −1 |
| Q3 2024 | 21 | +2 | 78.93M | $1.23B | +2 | n/a |
| Q2 2024 | 19 | n/a | 61.88M | $1.01B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 17.32M | -10.8% | $266.23M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 2 | Duquesne Family Office ✦ | 14.88M | +65.4% | $228.70M | 7.7% | ▲ Add | 3 | SEC ↗ |
| 3 | Glenview Capital ✦ | 14.78M | +74.8% | $227.15M | 5.6% | ▲ Add | 4 | SEC ↗ |
| 4 | Viking Global Investors ✦ | 10.13M | +55.7% | $155.63M | 0.5% | ▲ Add | 3 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 9.19M | -0.9% | $140.57M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 6 | Millennium Management ✦ | 5.50M | -16.0% | $84.47M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 7 | Renaissance Technologies ✦ | 5.30M | -24.0% | $81.48M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 2.85M | +19.6% | $43.85M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 9 | Norges Bank ✦ (passive) | 2.59M | +47.8% | $39.73M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | Greenlight Capital (DME Capital) ✦ | 568.20K | +21.3% | $8.73M | 0.4% | ▲ Add | 4 | SEC ↗ ×2 |
| 11 | Adage Capital Partners ✦ | 484.00K | -59.7% | $7.44M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 405.69K | -80.2% | $6.24M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 13 | Wellington Management ✦ | 138.14K | -25.7% | $2.12M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 14 | Two Sigma Investments ✦ | 136.80K | -80.1% | $2.10M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 15 | GAMCO Investors ✦ | 93.20K | -11.7% | $1.43M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 16 | ARK Investment Management ✦ | 90.25K | -10.2% | $1.39M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 17 | D. E. Shaw & Co. ✦ | 81.18K | -96.8% | $1.25M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 23.95K | +24.6% | $368,195 | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Arrowstreet Capital | $154.07M | was 0.1% |
| Marshall Wace | $113.63M | was 0.1% |
| Bridgewater Associates | $207,022 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 646 holders, 666.61M shares, $16.70B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.52K sh · $98,841
Director · 367.60K sh · $14.36M
Officer · 4.50K sh · $174,221
Officer · 314 sh · $12,153
Officer · 2.50K sh · $94,077
Director · 415 sh · $15,459
Officer · 6.95K sh · $261,224
Officer · 18.60K sh · $680,291
Director · 17 sh · $593
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology